ESMO 2024: Key Insights into Platinum-Resistant Ovarian Cancer Treatment
Promising Results from Phase 1/2 IL-Believe Trial
The ESMO 2024 conference showcased groundbreaking research on Platinum-Resistant Ovarian Cancer. Ascendis provided updates on their IL-Believe Trial, emphasizing notable findings.
Key Findings
- Breathtaking anti-tumor clinical responses in 29% of patients.
- 14 patients were efficacy-evaluable, spotlighting the potential of TransCon IL-2 β/γ treatment.
This research underscores the evolving landscape of treatments targeting Platinum-Resistant Ovarian Cancer.
Disclaimer: The information provided on this site is for informational purposes only and is not intended as medical advice. We are not responsible for any actions taken based on the content of this site. Always consult a qualified healthcare provider for medical advice, diagnosis, and treatment. We source our news from reputable sources and provide links to the original articles. We do not endorse or assume responsibility for the accuracy of the information contained in external sources.
This article was prepared using information from open sources in accordance with the principles of Ethical Policy. The editorial team is not responsible for absolute accuracy, as it relies on data from the sources referenced.